Medscape |
CHMP Backs Mepolizumab for Severe Eosinophilic Asthma
Medscape The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of mepolizumab (Nucala, GlaxoSmithKline) for add-on maintenance treatment in adults with severe refractory eosinophilic asthma, … EU regulator backs approval for GSK injectable asthma drug GlaxoSmithKline's asthma injection heads for EU approval Glaxo asthma drug clears key hurdle in Europe |
View full post on asthma – Google News